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Abstract. 
Although positron emission tomography/computed tomography (PET/CT) is a sensitive 
tool for Hodgkin’s lymphoma (HL) staging and response evaluation, its role in early detection 
of disease relapse remains controversial. A high false positivity of routine PET/CT during fol-
low-up may result in unnecessary treatment of HL patients who are in complete remission. 
Here we report a 15-year-old boy who had a false positive PET/CT result during his follow-up. 
Debulking surgery was performed for the suspicious lesion, which showed xanthogranuloma-
tous inflammation, fibrosis, old hemorrhage and fibrous adhesion of thymic tissue and pleura, 
but no residual tumor cells. One year after the surgery, this patient remained well without any 
evidence of disease relapse. Our case shows that PET/CT could provide false positive imaging 
in HL patients who are in complete remission after treatment. Tissue biopsy remains the really 
necessary tool of confirming disease relapse in patients with HL. 
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中文摘要 
  雖然正子電腦斷層攝影對何杰金氏淋巴瘤的分期及評估治療反應為一相當敏感的工
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 具，但針對早期發現疾病復發的角色仍無定論。因正子電腦斷層攝影用於常規追蹤時有
較高的偽陽性，容易導致已有完全緩解的患者接受不必要的治療。我們報告的病例是一
位 15 歲少年，於接受正子電腦斷層攝影追蹤時發生了偽陽性。腫瘤減積手術的病理報告
發現有黃色肉芽腫性發炎（xanthogranulomatous inflammation）、纖維化、陳舊出血、及胸
腺與肋膜的纖維沾黏，但卻沒有殘餘癌細胞。經手術一年後，該患者仍恢復良好、沒有
疾病復發的跡象。這個病例說明了正子電腦斷層攝影用於治療後已達完全緩解的何杰金
氏淋巴瘤患者追蹤時可能發生偽陽性，因此組織切片仍是何杰金氏淋巴瘤患者在確認疾
病復發時的主要依據。 
 
關鍵字: 何杰金氏淋巴瘤、正子電腦斷層攝影、偽陽性 
INTRODUCTION 
Positron emission tomography/computed tomog-
raphy (PET/CT) is widely used for staging, response 
evaluation and disease recurrence detection in Hodg-
kin’s lymphoma (HL) [1]. As compared with conven-
tional evaluation, PET/CT provides more accurate 
staging and strong prediction of treatment outcome. 
According to a prospective study conducted by 
Hutchings et al. [2], PET/CT has a higher diagnostic 
accuracy than CT in HL staging. Compared with CT, 
16% of patients are upstaged by PET/CT. On the con-
trary, only 5% of patients are downstaged. The change 
of disease stage leads to different treatment strategies 
in 7% of patients. A recent study by El-Galaly et al. [3] 
proposes that PET/CT staging may help to omit rou-
tine bone marrow biopsy, which does not change the 
risk assessment or treatment strategy. Also, many pre-
vious studies [4] have demonstrated that patients’ sur-
veillance PET/CT is more predictive in both progres-
sion-free survival (PFS) and overall survival (OS) af-
ter treatment of HL. However, a high false positivity 
of routine PET/CT during follow-up seems to be a 
challenge, which might result in overtreatment to HL 
patients who are in complete remission. Herein, we 
present a 15-year-old boy who had a false positivity of 
PET/CT after successful treatment of his HL.  
 
CASE REPORT 
A 15-year-old boy, without any inherited diseases 
or other previous systemic diseases, presented with 
productive cough for one month, accompanied by 
poor appetite and night sweats. His body weight de-
creased from 86 to 79 kilograms in two months as 
well. Physical examination showed no neck, axillary, 
or inguinal lymphoadenopathy. His liver and spleen 
were not palpable. Laboratory examinations showed 
leukocytosis (27,000/mm3; normal range, 4,000- 
11,000/mm3), an elevated erythrocyte sedimentation 
rate (64 mm/hr; normal range, 0-15 mm/hr), and nor-
mal liver and renal functions. However, computed 
tomography (CT) of the chest demonstrated a large 
hypervascular tumor in the left anterior mediastinum, 
which was about 11.5 cm in maximal diameter. Sever-
al small lymph nodes within 2 cm were also found in 
the upper mediastinum. A sonography-guided biopsy 
of the mediastinal mass revealed nodular sclerosing 
Hodgkin's lymphoma (Figure 1A), which was positive 
for CD30 (Figure 1B) and CD15 (not shown), but 
negative for CD20 (Figure 1C), immunohistochemi-
cally. Gallium-67 scintigraphy confirmed the results 
obtained from CT (Figure 2). Bone marrow examina-
tion presented no evidence of lymphoma involvement. 
He was diagnosed to have Hodgkin's lymphoma, stage 
IIX. 
For his stage IIX HL, he started to receive two  
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Figure 1. A. Hematoxylin-eosin (H&E) stain showing inflammatroy background, mixed with neutrophils, small 
lymphocytes and eosinophils. Scattered infiltration of large cells (arrows) with large round to oval nu-
clei were also seen (original magnification x 400). B. Immunohistochemical staining showing positive 
CD30 with membranous and focal para-Golgi apparatus pattern of those large cells (original magnifi-
cation x 400). C. Only small lymphocytes in the background stained positive by CD20 (original magni-
fication x 400). D. H&E stain showing xanthogranulomatous inflammation, cholesterol cleft, fibrosis, 
and old hemorrhage, but no residual tumor cells (original magnification x 100) 
 
 
cycles of chemotherapy with the ABVD regimen 
(doxorubicin 25 mg/m2, bleomycin 10 U/m2, vinblas-
tine 6 mg/m2, and dacarbazine 375 mg/m2, day 1 and 
day 15, every 4 weeks). Thereafter, interim PET/CT 
showed an increased 18F-fluorodeoxyglucose (FDG) 
uptake in the left mediastinum, with a maximal stand-
ard uptake value (SUVmax) of 11.8 at 1 hour. This 
PET/CT also demonstrated increased FDG uptake on 
both sides of the neck and in both axillary regions (the 
highest SUVmax of 10.5 at 1 hour). Because of partial 
response, we continued another four cycles of chemo-
therapy with the ABVD regimen. After completing a 
total of six cycles of chemotherapy with the ABVD 
regimen, CT of the chest was performed, showing re-
sidual tumor, which was about 7 cm in maximal di-
ameter. With a SUVmax of 6.7 at 1 hour in the left me-
diastinum, subsequent PET/CT showed only partial 
regression. Moreover, a new FDG uptake was found  
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Figure 2. Gallium-67 scintigraphy showing increased 
uptake in the left upper thoracic region  
(arrow) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Positron emission tomography/computed 
tomography showing a lesion with FDG 
uptake in the left mediastinum, with  
SUVmax of 10.7 at 1 hour (Panel A and B) 
 
 
in the upper mediastinum. The SUVmax was 6.3 at 1 
hour. The new lesion from PET/CT suggested early 
relapse. 
Salvage chemotherapy with the ICE regimen 
(ifosfamide 5 g/m2 for one day, day 2; carboplatin 
AUC 5 for 1 day, day 2; etoposide 100 mg/m2 over 3 
days, day 1 to day 3) was performed. After three cycles 
of chemotherapy with the ICE regimen, the patient 
received autologous hematopoietic stem cell trans-
plantation conditioned by the BEAM regimen (BCNU 
300 mg/m2 for 1 day, day -6; etoposide 150 mg/m2 
over 5 days, day -5 to day -2; cytarabine 200 mg/m2 
over 5 days, day -5 to day -2; melphalan 140 mg/m2 
for 1 day, day -1). After successful engraftment occur-
ring on Day 9, the follow-up CT of the chest showed 
only partial remission. For residual disease, he re-
ceived a 27 Gy intensity-modulated radiotherapy. Un-
fortunately, the previous FDG uptake did not change 
significantly. As the patient was free of symptoms, he 
received close observation but no further treatment.  
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 He received another CT of the chest eight months 
after radiotherapy, which showed tumor size reduction. 
However, a lesion with a size of 4.3 x 2 cm remained. 
Moreover, PET/CT showed the SUVmax of 10.7 at 1 
hour and 14.3 at 3 hours in this area (Figure 3), con-
sistent with disease in progression. As the HL was 
considered to be in progression, debulking operation 
for the mediastinal tumor with video-assisted thora-
coscopic surgery was performed. Surprisingly, the 
pathological findings consisted merely of xanthogran-
ulomatous inflammation, fibrosis, old hemorrhage and 
fibrous adhesion of thymic tissue and pleura. No re-
sidual tumor was found (Figure 1D). One year after 
the surgery, this patient remained well without evi-
dence of disease relapse. 
 
DISCUSSION 
With modern therapy, Hodgkin’s lymphoma can 
now be cured in more than 90% of patients with early 
HL, and 70% in cases of advanced HL [5]. However, 
long-term complications for treatment have contrib-
uted to the patients’ mortality and morbidity, and the 
complications include early cardiovascular diseases, 
pulmonary dysfunction, and secondary malignancies 
[6]. Thus, HL needs a careful approach, since optimal 
treatment with efficacy and acceptable toxicity is ex-
tremely important. As compared to many approaches, 
PET/CT is now widely used for staging, response 
evaluation and relapse detection in patients with HL 
[1]. The guidelines from the National Comprehensive 
Cancer Network recommend routine surveillance with 
PET/CT for initial staging and final response evalua-
tion in patients with HL [7]. The role of PET/CT in 
disease interim evaluation and early detection of re-
lapse disease, however, remains controversial. 
A reduction in tumor size on CT is the most dom-
inant conventional methods for treatment response 
monitoring [8]. However, the malignant cells occupy 
only a small fraction of tumor volume in HL. Most of 
the remaining cells are reactive infiltrating cells, 
which are not directly affected by antitumor therapy 
[9]. Therefore, size reduction alone may not be an ac-
curate predictor for treatment response. Conversely, 
functional imaging with PET/CT enables early evalu-
ation of the metabolic changes in HL. Hutchings et al. 
[10] showed a strong association between early inter-
im FDG-PET and patients’ PFS (P <0.0001) and OS 
(P <0.03). A projected 5-year PFS for PET-negative 
and -positive patients were 91.5% and 38.5%, respec-
tively. In addition, a study conducted by Gallamini et 
al. [11] further demonstrated positivity of early inter-
im FDG-PET could be of superior prognostic value to 
the International Prognostic Score in advanced HL. 
False positivity of PET/CT during follow-up has 
been reported in several cases [12-15]. There are also 
some studies focused on this issue (Table 1). A multi-
center retrospective study by El-Galaly et al. [16] 
showed that the true and false positive rates of routine 
PET/CT in HL patients who achieved first remission 
were 5% and 17%, respectively. Since overall positive 
predictive value (PPV) was only 28%, the cost for 
each relapses found by routine PET/CT was high.  
Furthermore, Lee et al. [17] showed that the PPV of 
PET/CT and that of CT were 22.9% and 28.6%, re-
Table 1. Comparison with published studies for positron emission tomography in follow-up of HL patients 
References Patients Sensitivity Specificity PPV FP NPV 
El-Galaly et al. [16] 161 100% 82% 22% 17% 100% 
Lee et al. [17] 192 100% 92% 23% 8% 100% 
Levine et al. [18] 34 100% 84% 11% 16% 100% 
Crocchiolo et al. [19] 27 100% 70% 54% 30% 100% 
PPV, positive predictive value; FP, false positive rate; NPV, negative predictive value 
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 spectively (P=0.73) in HL patients who were in first 
remission, and so CT was not inferior. 
Based on previous studies, the possible etiologies 
contributing to false positivity of PET/CT include fi-
brosis, lymphoid hyperplasia, progressive transfor-
mation of germinal centers, abdominal wall hernia, 
thymic hyperplasia, human immunodeficiency virus- 
associated lymphadenopathy, and infection/inflammation 
[15,18,19]. For patients with HL, tumor cells can ex-
press a high level of glucose transporter 1 (GLUT1), 
enhancing glycolytic activity in the tumor cells [20].  
Moreover, GLUT1 expression can be observed in 
transformed germinal centers and hyperplastic folli-
cles, which could be one of the mechanisms responsi-
ble for false positive results of PET/CT in our patient.  
Inflammation was another possibility for false positiv-
ity of PET/CT in our patient. The pathological find-
ings from the mediastinal mass showed only benign 
changes with xanthogranulomatous inflammation 
(XGI), characterized by a destructive inflammatory 
process and accumulation of lipid-laden fibrous tissue 
and inflammatory cells [21]. False positivity of 
PET/CT has been reported in patients with XGI in the 
gallbladder and pancreas [22,23]. However, to the best 
of our knowledge, Hodgkin’s lymphoma-associated 
XGI has never been reported. Further studies are 
needed to clarify the relation between XGI and false 
positivity of PET/CT in patients with HL.  
In conclusion, we have reported a case of HL with 
false positivity of PET/CT during follow-up, which 
might be associated with XGI. Although PET/CT is a 
useful, sensitive tool for disease staging and response 
evaluation, tissue biopsy remains the method which is 
really necessary in confirming disease relapse in pa-
tients with HL.  
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